JPMorgan’s top biotech and pharma picks for the second half

JPMorgan’s top biotech and pharma picks for the second half

Biopharmaceutical stocks’ underperformance versus the broader market for a third-straight year is an opportunity for investors, according to JPMorgan. Analyst Chris Schott said in the firm’s June outlook for biopharma that the sector’s poor performance can be traced back to concerns over President Donald Trump’s tariffs and his ” most favored nation ” executive order. … Read more

Jim Cramer’s top 10 things to watch in the stock market Monday

Jim Cramer’s top 10 things to watch in the stock market Monday

My top 10 things to watch Monday, May 19 1. Bonds are crushing stocks this morning, with the 30-year Treasury yield north of 5% and the 10-year Treasury yield topping 4.5%, in response to Moody’s downgrading its rating on U.S. sovereign debt. The S & P 500 is on track to open lower by about … Read more

These are the 4 biggest things we’re watching in the stock market in the week ahead

These are the 4 biggest things we’re watching in the stock market in the week ahead

The stock market heads into Monday on a streak of volatility it just can’t seem to shake. What had been shaping up as a positive holiday-shortened week turned on a dime Wednesday when Federal Reserve Chairman Jerome Powell signaled concern that President Donald Trump ‘s tariffs could increase inflation and slow economic growth. Speaking at … Read more

Abbott Labs shares surge on earnings and a big sign of confidence in the business

Abbott Labs shares surge on earnings and a big sign of confidence in the business

Shares of Abbott Laboratories jumped Wednesday after the diversified health-care company delivered strong first-quarter results and left its earnings guidance intact — a big sign of confidence in an uncertain time. Revenue in the three months ended March 31 rose 4% to $10.36 billion, narrowly missing the consensus of $10.4 billion, according to estimates compiled … Read more

Hard-hit Apple bounces back with the market, and an analyst is divided on our drug stocks

Hard-hit Apple bounces back with the market, and an analyst is divided on our drug stocks

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. Wall Street surged Tuesday on increased hopes of tariff deals, following a wickedly volatile session Monday. The Dow Jones Industrial Average climbed around 1,400 points, or 3.7%. The S … Read more

Life science stocks are under pressure due to possible NIH funding cuts. What lies ahead for the sector

Life science stocks are under pressure due to possible NIH funding cuts. What lies ahead for the sector

A recent move by the Trump administration to substantially lower funding from the National Institutes of Health for research institutions around the country has investors fearing meaningful losses for life science tools companies. The NIH announced in early February that it would cap research funding at 15% for “indirect costs” – those that aren’t directly … Read more

What Cramer wants to hear from Nvidia, Salesforce — plus, Lilly does what no other can

What Cramer wants to hear from Nvidia, Salesforce — plus, Lilly does what no other can

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. 1. The broader market rebounded Wednesday, with the S & P 500 and Nasdaq trying to snap their four-day losing streaks. The Dow was on pace for its third straight … Read more